反式-3-氨基-4-羟基-四氢吡喃盐酸盐 | 1630906-89-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 反式-3-氨基-4-羟基-四氢吡喃盐酸盐
• 英文名称: trans-3-Aminotetrahydro-2H-pyran-4-ol hydrochloride
• 英文别名: (3S,4S)-3-aminooxan-4-ol;hydrochloride
• CAS: 1630906-89-6
• 化学式: C5H12ClNO2
• 分子量: 153.61
• InChiKey: SFJKFFBPVORSEB-FHAQVOQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.48
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US10548899B2

  公开（公告）日：2020-02-04

  The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

  本发明提供了一种具有胆碱能肌动蛋白M1受体阳性变构调节剂活性的化合物，可能作为药物使用，例如作为预防或治疗阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、Lewy体痴呆等的药剂。本发明涉及一种由式（I）表示的化合物或其盐。在式（I）中，每个符号如所附说明书中所述。
• [EN] 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR<br/>[FR] DÉRIVÉS DE 2,3-DIHYDRO-4 H-1,3-BENZOXAZIN-4-ONE COMME MODULATEURS DU RÉCEPTEUR M1 MUSCARINIQUE CHOLINERGIQUE
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2016208775A1

  公开（公告）日：2016-12-29

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

  本发明提供一种具有胆碱能乙酰胆碱受体M1阳性变构调节剂活性的化合物，该化合物可能用作治疗或预防阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、李威氏体痴呆等疾病的药物。本发明涉及一种由式(I)或其盐表示的化合物：其中每个符号如附图中所定义。
• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10087150B2

  公开（公告）日：2018-10-02

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

  本发明提供了一种具有胆碱能毒蕈碱 M1 受体正异位调节剂活性的化合物，该化合物可用作阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、路易体痴呆等的预防或治疗药物。本发明涉及一种由式（I）代表的化合物或其盐： 其中各符号如所附说明书中定义。
• 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10323027B2

  公开（公告）日：2019-06-18

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

  本发明提供了一种具有胆碱能毒蕈碱M1受体正异位调节剂活性的化合物，它可作为阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、路易体痴呆等的预防或治疗药物。本发明涉及一种由式（I）代表的化合物或其盐：其中各符号如所附说明书中定义。
• 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3313836A1

  公开（公告）日：2018-05-02